A Phase I Study of Immune Checkpoint Inhibition (Anti-CTLA4 and/or Anti-PD-L1) in Combination With Radiation Therapy in Patients With Unresectable and Non-metastatic Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 07 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Dec 2017.
- 07 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Dec 2017.
- 07 Sep 2017 Status changed from not yet recruiting to recruiting.